ALMONTY INDUSTRIES INC. (ALM)
Lebrikizumab delivered long-term disease control for up to four years in patients with moderate-to-severe atopic dermatitis
Lebrikizumab delivered long-term disease control for up to four years in patients with moderate-to-severe atopic dermatitis
📈 **POSITIVE** • Medium confidence analysis (73%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business